[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:raf1-wt-allele":3},{"name":4,"total":5,"recruiting":6,"trials":7},"RAF1 wt Allele",4,3,[8,16,22,29],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04775485","A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors",[12],"Phase 2","RECRUITING","2026-08-26T02:18:45.196599Z","2026-05-05T02:43:29.733815Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05828069","A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis",[12],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:29.729634Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT05786924","Phase 1\u002F2 Trial of S241656 in Selected RAS\u002FMAPK Mutation- Positive Malignancies",[26],"Phase 1\u002FPhase 2","2026-08-26T02:16:54.044282Z","2026-05-05T02:35:31.640479Z",{"nct_id":30,"title":31,"phases":32,"status":34,"updated_at":35,"content_modified":36},"NCT05566795","DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC\u002FFIREFLY-2)",[33],"Phase 3","ACTIVE_NOT_RECRUITING","2026-08-03T03:35:11.971762Z","2026-05-05T02:35:31.694991Z"]